RootK KRX:195990KOSDAQ
에이비프로바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, RootK reported revenue of ₩9.0bn, down 1.1% year on year, and an operating loss of ₩4.1bn. RootK (에이비프로바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
RootK quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩9.0bn | -1.1% | −₩4.1bn margin −45.6% | −₩5.8bn |
| Q1 2026 | ₩7.9bn | -11.1% | −₩2.3bn margin −28.7% | ₩2.1bn |
| Q4 2025 derived | ₩6.1bn | -41.3% | −₩1.8bn margin −29.6% | −₩1.1bn |
| Q3 2025 | ₩7.9bn | -40.7% | −₩1.7bn margin −21.6% | −₩206m |
| Q2 2025 | ₩9.1bn | +365.6% | −₩2.5bn margin −27.7% | −₩44.4bn |
| Q1 2025 | ₩8.9bn | +45.3% | −₩3.3bn margin −36.8% | −₩3.3bn |
| Q4 2024 derived | ₩10.3bn | +69.9% | −₩3.5bn margin −34.0% | −₩22.2bn |
| Q3 2024 | ₩13.3bn | +198.7% | −₩1.6bn margin −12.3% | ₩8.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
RootK top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest RootK news Korean headlines
No articles yet.